Suchergebnisse

Disturbances in affect have been linked to problem behavior in adolescence and future psychopathology, but little is known about how such disturbances manifest themselves in everyday contexts. This study investigated daily mood in Dutch 7th graders, aged 11–14. Cluster analysis of problem measures distinguished high‐risk (n=25) and low‐risk (n=106) subgroups. Participants completed experience‐sampling reports of mood, social context, and location nine times daily for 5 days. Multilevel regression analyses of four mood measures confirmed higher anxiety and depressed mood in the high‐risk group. Moods varied by location and social context, with significant differences between groups in two specific social contexts. First, when with family, low‐risk adolescents felt less depressed than when alone, whereas high‐risk adolescents felt more depressed. Second, high‐risk adolescents showed more pronounced anxiety in social situations outside the network of family and friends. These findings point to everyday social contexts in which young adolescents with emotional and behavioral problems appear to be particularly vulnerable.

Abstract Empirical evidence suggests that a fair proportion of dementia cases are preventable, that some preventive actions can be taken immediately, and others may soon be implemented. Primary prevention may target cognitively normal persons with modifiable risk factors through lifestyle and multiple domain interventions (including general cardiovascular health). While the effect on individuals may be modest, it might have a large societal impact by decreasing overall dementia incidence by up to 35%. Secondary prevention will target cognitively normal persons at high risk of dementia due to Alzheimer's disease pathology with future anti‐amyloid, anti‐tau, or other drugs. This approach is likely to have major benefits to both individuals and society. Memory clinics will need structural and functional changes to adapt to novel technologies and increased patients' demands, and brand‐new services may need to be developed with specific skills on risk profiling, risk communication, and personalized risk reduction plans. ; The authors receive funding by the European Prevention of Alzheimer's Dementia consortium (EPAD, grant agreement number: 115736), Amyloid imaging to prevent Alzheimer's disease (AMYPAD, grant agreement number: 115952), NIHR biomedical research center at UCLH, Joint Programming for Neurodegenerative Diseases (JPND-Euro-FINGERS, ZonMW #733051102), health-Holland, Top Sector Life Sciences & Health (Personalized Prevention, grant no.: LSHM19051-H036). This publication solely reflects the author's view and neither IMI nor the European Union, EFPIA and JPND are responsible for any use that may be made of the information contained herein.

Abstract Introduction: Reimbursement of amyloid-positron emission tomography (PET) is lagging due to the lack of definitive evidence on its clinical utility and cost-effectiveness. The Amyloid Imaging to Prevent Alzheimer's Disease-Diagnostic and Patient Management Study (AMYPAD-DPMS) is designed to fill this gap. Methods: AMYPAD-DPMS is a phase 4, multicenter, prospective, randomized controlled study. Nine hundred patients with subjective cognitive decline plus, mild cognitive impairment, and dementia possibly due to Alzheimer's disease will be randomized to ARM1, amyloid-PET performed early in the diagnostic workup; ARM2, amyloid-PET performed after 8 months; and ARM3, amyloid-PET performed whenever the physician chooses to do so. Endpoints: The primary endpoint is the difference between ARM1 and ARM2 in the proportion of patients receiving a very-high-confidence etiologic diagnosis after 3 months. Secondary endpoints address diagnosis and diagnostic confidence, diagnostic/therapeutic management, health economics and patient-related outcomes, and methods for image quantitation. Expected impacts: AMYPAD-DPMS will supply physicians and health care payers with real-world data to plan management decisions. Keywords: Alzheimer's disease; Amyloid-PET; Clinical validity; Cost-effectiveness; Mild cognitive impairment; Subjective cognitive decline. ; This work has received support from the EU-EFPIA Innova-tive Medicines Initiatives 2 Joint Undertaking (grant no.115952). This publication solely reflects the author's view and neither IMI nor the European Union, and EFPIA are responsible for any use that may be made of the information contained herein.